Gilead deliberately withheld a much safer version of HIV drugs from the market for more than a decade in a patent-timing scheme to maximize profits. But there, nobody knew about the safer drug. Lots of people know about leronlimab in the oncology world.

That is a possibility if Leronlimab were for one indication, but I would imagine a much more difficult proposition with dozens of applications. I think if BP were to buy the drug the cat would get out of the bag for numerous disease possibilities.